Additionally, glycolysis plays a critical role in the treatment of Parkinson’s disease, and terazosin has been shown to activate the enzymatic activity of phosphoglycerate kinase 1 (PGK1) (22, 41). The gene discussed is PGK1; the disease is Parkinson disease.